Slide 1: Corporate Presentation
Corporate Presentation June 2025 Version:6/4/2025
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are subject t
Slide 3: Who is CorMedix?
Who is CorMedix? • CorMedix is a publicly listed (Nasdaq: CRMD), small cap, commercial stage biopharma company developing therapeutic products for the prevention and treatment of life-threatening conditions and diseases • DefenCath® (taurolidine and heparin) is an FDA approved, first-in-class, non-a
Slide 4: DefenCath Launch Statistics
DefenCath Launch Statistics • CorMedix has commercial agreements in place with 4 of the top 5 outpatient DOs, or ~60% of outpatient dialysis clinics, with 3 midsized dialysis operators (MDOs) beginning implementation in 2024, and one large dialysis operator (LDO) expected to begin implementation by
Slide 5: CorMedix Executive Leadership Team
CorMedix Executive Leadership Team JO INED CO RM EDIX PRIO R EXPERIEN CE • Chief Commercial Officer of Amneal Specialty Joe Todisco 2022 • Co-founder and Chief Executive of Gemini Laboratories Chief Executive Officer • Commercial Strategy and business development at Ranbaxy • Interim CEO of CorMedix
Slide 6: The Problem: CRBSI
The Problem: CRBSI Catheter Related Bloodstream Infections 6
Slide 7: Majority of Patients Needing Replacement Kidney Function Use Hemodialysis via CVC
The Majority of Patients who Need Replacement Kidney Function use Hemodialysis, and are Initially Treated through a CVC • ESRD – The advanced state of • ~60 – 70% of patients with ESRD or • CVC can be used immediately and is widely chosen at initiation chronic kidney disease in which AKI are treated
Slide 8: CVCs Responsible for ~70% of Access-related Bloodstream Infections
CVCs are Responsible for ~70% of Access-related Bloodstream Infections in Hemodialysis Patients Dialysis Patients by Access-Related Bloodstream Access Type Infection by Access Type CRBSIs can occur in 25-33% of CVC 100% 100% HD patients, and are caused by a wide range of pathogens-many of which ar
Slide 9: CRBSIs Result in Significant Patient Morbidity, Mortality and Cost
CRBSIs Result in Significant Patient Morbidity, Mortality and Cost to the Healthcare Systems Kaplan Meier Survival Estimate, Time to Death 40-50% of dialysis patients are considered high risk for infections No CRBSI CRBSI 1.0 Mortality occurs rapidly Infections are the second most common in patients
Slide 10: The Solution: DefenCath
The Solution: DefenCath DefenCath® (taurolidine and heparin) catheter lock solution (CLS) is FDA approved to reduce the incidence of catheter-related bloodstream infections (CRBSIs) for the limited population of adult patients with kidney failure receiving chronic hemodialysis through a central veno
Slide 11: First and Only FDA Approved Catheter Lock Solution with Significant Risk Reduction
DefenCath is the First and Only FDA Approved Catheter Lock Solution with Significant Risk Reduction in CRBSIs • First and only FDA-approved antimicrobial catheter lock solution • Broad antimicrobial activity against common Gram-positive and Gram- negative bacteria, multi-drug resistant bacteria, and
Slide 12: Significant Reduction in CRBSI Risk in Phase 3 LOCK-IT-100 Study
DefenCath Demonstrated Significant Reduction in CRBSI Risk in the Phase 3 LOCK-IT-100 Study Full Study Total CRBSIs (D / H) 41 (9 D / 32 H) Total Subjects 795 Reduction in Risk of CRBSIs 71% p-value 0.001 -71% Overall, fewer patients had catheters 0.6 removed due to CRBSIs with DefenCath 0.5 compare
Slide 13: Safety Profile and Usage Logistics Support Widespread Adoption
Safety Profile and Usage Logistics Support Widespread Adoption Safety • Safety profile comparable to heparin CLS control (current SoC) • Similar catheter patency and catheter removal frequency to heparin control arm • No demonstrated antimicrobial resistance Logistics • Stored at room temperature •
Slide 14: The Opportunity
The Opportunity DefenCath® has a clear and compelling value proposition across both inpatient and outpatient dialysis channels to help reduce infection risk, provide savings / reduce missed revenue, and reduced patient mortality 14
Slide 15: Well Positioned To Capture Value Across Outpatient And Inpatient Markets
DefenCath Is Well Positioned To Capture Significant Value Across Both Outpatient And Inpatient Markets Outpatient Inpatient ~37MM vials for ESRD patients ~3.8MM vials for ESRD and AKI Patients (Total annual addressable market) (Total annual addressable market) Reduce Missed Dialysis Sessions Signifi
Slide 16: Commercial Execution & Strategy
Commercial Execution & Strategy DefenCath® launched in the inpatient setting April 15, 2024 and in the outpatient setting July 1, 2024 • Based on concentrated markets and focus on key decision makers, modest infrastructure required for launch • CorMedix field sales team consists of 28 Field Based De
Slide 17: Expansion
Expansion Taurolidine and Heparin Catheter Lock Solution has potential to show efficacy in the prevention of bloodstream infections in other patient populations 17
Slide 18: CorMedix Plans to Pursue Additional Indications for Taurolidine/Heparin
CorMedix Plans to Pursue Additional Indications for Taurolidine/Heparin Combination • CorMedix aims to pursue other potential indications for taurolidine/heparin including Total Parenteral Nutrition (TPN), Pediatric HD (requirement under PREA), and Oncology • Commenced TPN study in 2Q 2025 on the pr
Slide 19: Infections are a Major Concern in TPN
Infections are a Major Concern in TPN, Due to the Unique Combination of Factors that Make these Patients More Likely to Get Infected Parenteral Nutrition 1-4 episodes of Drivers of Infections infection per 1,000 catheter days • Components of TPN: Sugars and lipids support growth of bacteria and fung
Slide 20: Infections in TPN Patients Increase Risk of Mortality and Other Negative Outcomes
Infections in TPN Patients Increase the Risk of Mortality and Other Negative Outcomes • CLABSIs are associated with an increased mortality rate of 12-25% • In addition to death, CLABSIs in TPN patients can lead to septic shock, organ damage or failure, or blood clotting CLABSIs are associated with a
Slide 21: TPN Represents a DefenCath Opportunity of ~4.7MM Infusions per Year
Across Outpatient and Inpatient Settings, TPN Represents a DefenCath Opportunity of ~4.7MM Infusions per Year US Total Parenteral Nutrition Total Addressable Market 2024E 4.0 Ports or IVs 3.6 3.5 CVCs, PICCs, or Midlines 0.5 Total Infusions (MM) 3.0 DefenCath Addressable Infusions 2.5 ~4.7MM 2.0 1.8
Slide 22: Financial Metrics
Financial Metrics ¥ CorMedix
Slide 23: Financial Highlights
Financial Highlights Key Statistics Balance Sheet as of 3/31/2025 Exchange NASDAQ Global Market Cash and short-term investments* $77.5 million** Common Stock 67.8 million shares as of 5/4/2025 Debt None Market cap*** ~$850 million Key Financials (1) 2025 Guidance Q4 2024 Net Revenue $31.2 million 1H
Slide 24: References
References 1. USRDS End Stage Renal Disease 2020 Annual Data Report; Chapter 3; Vascular Access 2. Araya S. et.al.; Racial and Sex Disparities in Catheter Use and Dialysis Access in the United States Medicare Population JASN 31: 625–636, 2020 3. LOCK-IT-100: CRMD003, A Novel Taurolidine-Based Cathet